中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 9
Sep.  2014
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2014  >  30(9): 869-872

Efficacy and safety of UCB- derived or autologous CIK cells combined with interferon therapy in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2014.09.008

  • Department of Infectious Diseases, 105 Hospital of PLA

  • Received Date: 2013-12-23
  • Published Date: 2014-09-20
    Abstract

  • Objective To investigate the efficacy and safety of umbilical cord blood ( UCB) - derived or autologous cytokine- induced killer ( CIK) cells combined with interferon therapy in patients with chronic hepatitis B ( CHB) . Methods Thirty CHB patients hospitalized in the Department of Infectious Diseases from October 2010 to June 2013 were included in the study. These patients were randomly and equally divided into first and second treatment groups and control group. The first or second treatment group underwent transplantation of UCB- derived or autologous CIK cells combined with interferon therapy; the control group received interferon therapy alone. At 4 and 12 weeks after treatment, alanine aminotransferase ( ALT) , serum hepatitis B virus ( HBV) marker, HBV DNA, and CD4+/CD8+ratio in peripheral blood were measured. Comparison of means was made by paired t test or independent- samples t test. Results At 12 weeks after transplantation of UCB- derived or autologous CIK cells, the first or second treatment group had ALT, HBeAg, and HBV DNA levels of ( 22. 6 ± 14. 4) or ( 32. 9 ± 15. 3) U /L, ( 12. 5 ± 5. 8) or ( 18. 4 ± 8. 8) PEIU /ml, and ( 3. 2 ± 0. 7) or ( 3. 7 ± 0. 6) log10 copies /ml, respectively, significantly lower than those for control group ( t = 2. 80 ~ 5. 45, P < 0. 05) . At 4 weeks after transplantation, the two treatment groups had significantly increased CD4+levels and CD4+/CD8+ratios compared with the control group ( t = 2. 21 ~ 2. 43, P < 0. 05) . No severe adverse reactions and transplantation- related severe complications were found in the two treatment groups. Conclusion For CHB patients, transplantation of UCB- derived or autologous CIK cells significantly inhibits virus replication rapidly, improves liver function, relieves clinical symptoms, improves cellular immunity, and has high safety.

     

    • FullText(HTML)
    • References(13)
  • [1]XU DZ.Clinical practice of viral hepatitis[M].Third Version.Beijing:People's Medical Publishing House, 2006:137-158. (in Chinese) 徐道振.病毒性肝炎临床实践[M].3版.北京:人民卫生出版社, 2006:137-158.
    [2] SIFT M, FU J, SHI F, et al.Transfusion of autologotm cytokitminduced killer cells inhibits viral replication in patients with chronic hepatitis B vius infection[J].Clin Immunol, 2009, 132 (1) :43-54.
    [3]SU HB, SHI M, MOU JS, et al.Effect of adoptive immunotherapy with autologous cytokine-induced killer cells on liver function in patients with chronic HBV infection[J].Chin Hepatol, 2007, 12 (2) :131-132. (in Chinese) 苏海滨, 施明, 牟劲松, 等.自体细胞因子诱导杀伤细胞过继性免疫治疗对慢性HBV感染患者肝功能的影响[J].肝脏, 2007, 12 (2) :131-132.
    [4]LI YY, SHI M, ZHANG B, et al.Research of the function of dendritic cell subsets in chronic hepatitis B patients after retransfusion treatment with autologous CIK cells[J].Infect Dis Info, 2008, 21 (2) :112-114. (in Chinese) 李元元, 施明, 张冰, 等.细胞因子诱导的自体杀伤细胞回输治疗慢性乙型肝炎患者树突状细胞功能的研究[J].传染病信息, 2008, 21 (2) :112-114.
    [5]Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline for prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会感染病学分会和肝病学分会.慢性乙型肝炎防治指南 (2010版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.
    [6] Ministry of Health.Regulation on the clinical application of medical technology[M].Beijing:Ministry of Health of the People's Republic of China, 2009. (in Chinese) 卫生部.医疗技术临床应用管理办法[M].北京:中华人民共和国卫生部, 2009.
    [7]LIN XF, WU JM, LIN CJ, et al.Effeets of HBV S-ecdCD 40L fusion gene modification on function of dendritic cells[J].J Med Res, 2013, 42 (12) :49-53. (in Chinese) 林贤凡, 吴金明, 林春景, 等.HBV S-ecdCD40L融合基因修饰对树突状细胞功能的影响[J].医学研究杂志, 2013, 42 (12) :49-53.
    [8]SHI M, WANG FS, ZHANG B, et al.Evaluation of safety and efficiency of treatment with autologous cytokine-induced killer cell for hepatocellular carcinoma[J].Med J Chin PLA, 2004, 29 (4) :333-335. (in Chinese) 施明, 王福生, 张冰, 等.自体CIK细胞治疗肝癌的安全性和有效性评价[J].解放军医学杂志, 2004, 29 (4) :333-335.
    [9]WANG W, ZHENG HW, REN GF, et al.Differential profiles of T-cell subsets are present in peripheral bolld of patients with various progressive forms of hepatitis B infection[J].J Clin Hepatol, 2013, 29 (4) :276-278. (in Chinese) 王慰, 郑欢伟, 任桂芳, 等.慢性HBV感染及其相关肝病患者外周血T细胞亚群的变化[J].临床肝胆病杂志, 2013, 29 (4) :276-278.
    [10]HUANG J, CHEN ZY.Dynamic observation of cytokine-induced killer cells in peripheral blood from patients with chronic hepatitis B[J].Chin J Cell Mol Immunol, 2003, 19 (6) :554-556. (in Chinese) 黄俭, 陈作严.慢性乙型肝炎患者外周血细胞因子诱导的杀伤细胞的动态观察[J].细胞与分子免疫学杂志, 2003, 19 (6) :554-556.
    [11] XIAO Q, ZHANG LL, SHEN BJ.Research advances in cord blood cytokine induced killer cells[J].Int J Pediatr, 2011, 38 (5) :500-501. (in Chinese) 肖琼, 张乐玲, 沈柏均.脐血CIK细胞的研究进展[J].国际儿科学杂志, 2011, 38 (5) :500-501.
    [12]DENG HF, LU MY, XU B, et al.Detection of survival time of cytokine-induced killer cells in vivo by specific DNA probes[J].Chin J Exp Surg, 2011, 28 (11) :1983-1985. (in Chinese) 邓海峰, 陆明阳, 徐斌, 等.特异性DNA探针检测细胞因子诱导的杀伤细胞在患者体内的生存时间[J].中华实验外科杂志, 2011, 28 (11) :1983-1985.
    [13]LAI N, LIU Q.Progress in adoptive immunotherapy for chronic hepatitis B[J].Chongqing Med J, 2002, 31 (11) :1119-1121. (in Chinese) 赖宁, 刘杞.慢性乙型肝炎过继免疫治疗的进展[J].重庆医学, 2002, 31 (11) :1119-1121.引证本文:LIU B, DONG J, ZHANG JF, et al.Efficacy and safety of UCB-derived or autologous CIK cells combined with interferon therapy in patients with chronic hepatitis B[J].J Clin Hepatol, 2014, 30 (9) :869-872. (in Chinese) 刘波, 董静, 张骏飞, 等.脐血来源或自体细胞因子诱导的杀伤细胞联合干扰素治疗慢性乙型肝炎的安全性和有效性分析[J].临床肝胆病杂志, 2014, 30 (9) :869-872.
    • Relative Articles

  • Relative Articles

    [1]Shiji CHENG, Tianrui KUANG, Keshuai DONG, Jia YU. Research advances in natural killer cell-based immunotherapy in liver cancer[J]. Journal of Clinical Hepatology, 2023, 39(6): 1476-1481. doi: 10.3969/j.issn.1001-5256.2023.06.034
    [2]Lijie MA, Chang YU, Fang WANG, Yifei TANG, Hailong WU, Xuehua SUN, Yueqiu GAO. Effect of naringenin on natural killer cell cytotoxicity against hepatocellular carcinoma cells in vitro and its mechanism[J]. Journal of Clinical Hepatology, 2022, 38(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2022.08.019
    [4]Wang HaiYan, Zhu Li, Wang YinLing, Zhu YuePing, Zhu XiaoYan, Chai XiaoZhe, Qian Feng, Li Ming, Zhu ChuanWu. Impact of pegylated interferon versus conventional interferon on the change in peripheral CD4+CD25highT cells in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(1): 53-57. doi: 10.3969/j.issn.1001-5256.2018.01.011
    [5]Wang ShaoYang, Lin TaoFa, Zhu LingLing, Xie LiPing. Establishment and functional evaluation of DC-CIK co-culture system with combined loading of HBsAg and HBcAg[J]. Journal of Clinical Hepatology, 2017, 33(7): 1280-1283. doi: 10.3969/j.issn.1001-5256.2017.07.015
    [6]Cao ZhenHuan, Liu YaLi, Ma LiNa, Lu JunFeng, Jin Yi, He ZhiMin, Zheng YanHong, Chen XinYue. Association between serum level of interleukin-17 and HBsAg clearance in patients with HBsAg-negative chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1292-1295. doi: 10.3969/j.issn.1001-5256.2016.07.015
    [7]Weng MeiLing, Zhang GuoLiang, Wu WenZe, Shi Mei, Liu LiLi. Association of chronic hepatitis B with interferon-γ and interleukin-4[J]. Journal of Clinical Hepatology, 2016, 32(10): 1989-1993. doi: 10.3969/j.issn.1001-5256.2016.10.039
    [8]Zhou Liang, Li XiaoYan, Huang YueHua. Regulatory effect of interleukin-10 on natural killer cells in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(8): 1600-1603. doi: 10.3969/j.issn.1001-5256.2016.08.040
    [9]Lu Ying. Correlation of serum interleukin-33 with HBV DNA load and ALT level in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(11): 1853-1856. doi: 10.3969/j.issn.1001-5256.2015.11.020
    [10]Wang ShaoYang, Lin TaoFa, Liu HaiZhou, Ma WeiMin, Xie ZhiHong. A clinical study of autologous cytokine-induced killer cells in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(4): 530-533. doi: 10.3969/j.issn.1001-5256.2015.04.013
    [11]Liu LiWei, Li JiaJia, Zhu LiXin, Liu Bo. In vitro proliferation capacity and killing efficacy of CIK cells from umbilical cord blood versus patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(9): 873-876. doi: 10.3969/j.issn.1001-5256.2014.09.009
    [12]Shi QingFeng, Zhang YingXin, Song JiKui, Yuan JianGuo, Li QingFang, Zhao HongKui, Ceng WeiQun, Chen Min. Effect of prostaglandin E1 on the dendritic cells maturation and the activity of CD4+/CD8+ T cells in chronic severe hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(3): 212-215.
    [13]Yan ShuangHuan, Cao ZhiChen. Changes in Toll-like receptor 4 expression on the surface of peripheral blood monocytes in patients with chronic hepatitis B during interferon treatment [J]. Journal of Clinical Hepatology, 2012, 28(11): 828-830.
    [14]Shi QingFeng, Song JiKui, Zhang YingXin, Yuan JianGuo, Wang SiKui, Li QingFang, Zhao HongKui. Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b[J]. Journal of Clinical Hepatology, 2011, 27(12): 1285-1287+1300.
    [15]Zhou DongFang, Hu ChaoGang, Zhou JunYing. NK cells and hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(12): 1341-1344.
    [16]Feng Fei, Ma Li, Cui HongLing, Liu JingFang. The Adefovir dipivoxil presses the liver cell growth hormone treatment chronic type B heavy hepatitis curative effect observation jointly[J]. Journal of Clinical Hepatology, 2010, 26(6): 594-595.
    [17]Xi HongLi, Liu FangFang, Yuan JiaYing, Yu YanYan. Significance and detection of IL-2、IL-4 and IFN-γ in PBMC from patients with hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2010, 26(6): 627-629.
    [18]Cheng QianGang, Zhao HaiHong. Clinlical effect and safety of PegIFN α-2a in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2007, 23(6): 424-426.
    [19]Zhu ChuanWu, Qian Feng, Wang HaiYan, Li Ming, Chang JianGuo, Zhang XueHua, Xu KeLing, Wang YongPing, Gao ShengLan, Tong FuYi. Effect of Interferon-α therapy on production of IL-12 secreted by peripheral blood dendritic cells in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2004, 20(2): 77-79.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.3 %FULLTEXT: 4.3 %META: 93.2 %META: 93.2 %PDF: 2.5 %PDF: 2.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.8 %其他: 4.8 %其他: 0.3 %其他: 0.3 %China: 0.5 %China: 0.5 %India: 0.3 %India: 0.3 %Russian Federation: 0.3 %Russian Federation: 0.3 %Taiwan, China: 1.0 %Taiwan, China: 1.0 %上海: 2.3 %上海: 2.3 %北京: 5.8 %北京: 5.8 %南宁: 0.3 %南宁: 0.3 %台州: 0.3 %台州: 0.3 %吉林: 0.8 %吉林: 0.8 %哥伦布: 0.5 %哥伦布: 0.5 %天津: 0.3 %天津: 0.3 %广州: 0.5 %广州: 0.5 %张家口: 4.5 %张家口: 4.5 %成都: 0.3 %成都: 0.3 %杭州: 1.3 %杭州: 1.3 %格兰特县: 0.3 %格兰特县: 0.3 %芒廷维尤: 32.6 %芒廷维尤: 32.6 %芝加哥: 0.3 %芝加哥: 0.3 %莫斯科: 1.0 %莫斯科: 1.0 %西宁: 41.7 %西宁: 41.7 %长春: 0.5 %长春: 0.5 %其他其他ChinaIndiaRussian FederationTaiwan, China上海北京南宁台州吉林哥伦布天津广州张家口成都杭州格兰特县芒廷维尤芝加哥莫斯科西宁长春

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2776) PDF downloads(548) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2490]YesterdayPV[5108]TodayIP[2440]TodayPV[4851]Online[85]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return